65
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Decreased mean platelet volume in panic disorder

, , &
Pages 1665-1669 | Published online: 04 Sep 2014

Abstract

Aim

The relationship between psychological stress and platelet activation has been widely studied. It is well known that platelets may reflect certain biochemical changes that occur in the brain when different mental conditions occur. Platelet 5-hydroxytryptamine (5-HT) is also extensively studied in psychiatry. The mean platelet volume (MPV), the accurate measure of platelet size, has been considered a marker and determinant of platelet function. The aim of the present study was to search for any probable difference in the MPV of subjects with panic disorder (PD).

Methods

A total of 37 drug-free subjects, aged 18 to 65 years, diagnosed with PD, with or without agoraphobia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth edition (DSM-IV) criteria and 45 healthy control subjects were included in the study. Platelet count and MPV were measured and recorded for each subject.

Results

There were no statistically significant differences between groups in terms of female/male ratio, age, or body mass index between the PD group and control group (P=0.91, P=0.82, and P=0.93, respectively). The MPV was found to be significantly lower in the PD group compared with the control group (8.8±0.9 fL vs 9.2±0.8 fL; P=0.02). All the participants had MPV values in the standard range of 6.9–10.8 fL.

Conclusion

We concluded that abnormalities of the 5-HT1A receptor function in the central nervous system of subjects with a diagnosis of PD are also mirrored in as an alteration in platelet activity. Measurements of platelet activity may be used as a tool for neuropsychiatric and psychopharmacological research and for studying how certain mental diseases and medications affect the central nervous system.

Introduction

Serotonin (5-hydroxytryptamine [5-HT]) is well established as a neurotransmitter in the central nervous system (CNS), but it also plays diverse roles in the vascular system, including platelet aggregation and regulation of vascular tone.Citation1 Researchers have suggested platelet activity is increased by emotional stress and hypothesized that the actions of stressors on platelets may be a primary trigger in such coronary events as myocardial infarction.Citation2 Platelet uptake of 5-HT from the plasma is dependent on the 5-HT transporter, commonly regarded for its role in neurotransmitter reuptake in the CNS but also essential to the platelet plasma membrane.Citation3 Platelet 5-HT has been extensively studied in psychiatry. Some studies have reported increased platelet 5-HT2A receptor density (expressed as maximum binding [Bmax]) in unipolar depression. Some have reported a positive correlation between platelet 5-HT2A receptor density and the Hamilton Depression Rating Scale suicidality item or loss of impulse control in suicide attempts.Citation4Citation6

5-HT is also important in the pathophysiology of pain in migraine,Citation7,Citation8 while the polymorphism of the 5-HT transporter gene appears to be associated with increased risk of migraine.Citation9 Borgdorrf and Tangelder reviewed the evidence that release of platelet 5-HT and platelet activation, by shear stress, may be important in migraine.Citation10 They mentioned that platelets might be damaged or activated by a cardiovascular abnormality, eg, a symptomatic patent foramen ovale. Sarchielli et al suggested that the increased production of platelet-activating factor may account for persistent platelet activation during migraine crises.Citation11 Ginkgolide B, a herbal constituent extract from Ginkgo biloba tree leaves, was considered as a promising pharmacological aid for the treatment of migraine in adult patients because of its modulation of the antiplatelet activating factor.Citation12

The blood–brain relationship between platelets and the neuronal 5-HT transporter is supported by several lines of evidence, such as the correlation of platelet and synaptosomal reuptake, similar changes of human blood and cerebrospinal fluid 5-HT levels parallel changes of blood and brain 5-HT levels after administration of 5-HT-releasing drugs, and the association of depression with an increased risk of vascular events related to platelet dysfunction.Citation13 Also, a meta-analysis reconfirmed initial reports of an association between platelet 5-HT uptake and depression.Citation14

Although many studies have been conducted on panic disorder (PD), the etiology of this debilitating disorder is still poorly understood.Citation15 Recent research has linked abnormal 5-HT neurotransmission to the pathophysiology of PD.Citation16 Catechol-O-methyltransferase (COMT) and 5-HT receptor 2A (5-HTR2A) polymorphisms have been investigated for their possible role in PD, and Karaçetin et al found that the COMT Val158Met polymorphism was significantly associated with PD, in a Turkish population of PD patients.Citation17

Platelets may reflect certain biochemical changes that occur in the brain when different mental conditions occur.Citation18 The mean platelet volume (MPV), the accurate measure of platelet size, has been considered a marker and determinant of platelet function. Increased MPV may reflect either increased platelet activation or increased numbers of large, hyperaggregated platelets.Citation19

This nonrandomized case-control study aimed to examine the MPV in patients with PD compared with healthy controls. It was hypothesized that subjects with PD have lower MPV levels compared with healthy controls. To our knowledge, this is the first study investigating the correlation of levels of MPV with PD.

Methods

Thirty-seven drug-free subjects aged 18 to 65 years who were diagnosed with PD, with or without agoraphobia, according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria were included in the study. Forty-five subjects with similar sociodemographic characteristics and body mass index were included as a control group. Subjects included in the study were interviewed with the Structured Clinical Interview Diagnostic-I for DSM-IV.Citation20 Patients with comorbid dysthymia, generalized anxiety disorder, or major depression were included if PD was judged as the principal diagnosis. Healthy control subjects with no personal history of psychiatric or physical disorder were hospital employees or were recruited through local advertisements. Sociodemographic data, height, body weight, and MPV were measured and recorded for each subject. Subjects who had seizure disorders, mental retardation, autistic disorder, organic brain damage, psychotic disorder, conduct disorder, hypertension, hypercholesterolemia, other acute or chronic physical illnesses, pregnancy, or a history of any drug use during the last month or smoking were excluded from the study.

The study was approved by the local medical ethics committee of Uskudar University, and written informed consent was obtained from each patient.

Blood sampling

Blood samples were drawn from each subject after a fasting period of 12 hours. In the fasting venous blood samples, collected with K3EDTA-containing sterile Vacutainer™ tubes, complete blood counts, including MPV, were determined using an Abbott CELL-DYN Sapphire® automated hematology analyzer (Abbott Laboratories, Abbott Park, IL, USA) with its own commercial kits. In order to measure MPV reliably and to minimize the potential influence of anticoagulant (ethylenediaminetetraacetic acid [EDTA]) on the MPV, blood samples were analyzed within 60 minutes after venipuncture. Platelet count and MPV were measured and recorded for each subject. The reference range for MPV was between 6.9–10.8 fL. All the blood samples were analyzed at the same laboratory (which participated in an external quality assurance program for the hemogram). The samples were analyzed daily, and only one batch was used for all the samples on each day, to avoid systemic inconsistency among batches. To assure quality, quality control samples were included in the run of the batches. The control samples confirmed the accuracy of results. Although automated hemogram analysis was used in this study, blood smear examination was also used to provide a visual confirmation of the automated instrument results.

Statistics

The data was analyzed using SPSS for Windows, Version 16.0 software (SPSS, Inc., Chicago, IL, USA). The differences in numerical variables between groups were analyzed by the t-test and Mann–Whitney U-test, and the differences in categorical variables were analyzed by chi-square analysis. Odds ratio and 95% confidence intervals (CIs) were used for the assessment of risk factors. A P-value less than 0.05 was considered as statistically significant.

Results

The PD group consisted of 21 females (56.8%) and 16 males (43.2%), and there were 25 females (55.6%) and 20 males (44.4%) in the control group. Mean ages were 34.06±9.5 years in the PD and 35.8±10 years in the control group. Mean body mass index was found to be 23.67±4.1 kg/m2 and 23.64±2.9 kg/m2 in the PD and control group, respectively. There were no statistically significant differences between groups, in terms of female/male ratio, age, or body mass index between the PD group and control group (P=0.91, P=0.82, and P=0.93, respectively). The MPV was found to be significantly lower in the PD group compared with the control group (8.8±0.9 fL and 9.2±0.8 fL, respectively; P=0.02) ( and ). All the participants had MPV values in normal range of 6.9–10.8 fL.

Figure 1 Bar chart of the panic disorder and healthy control groups in terms of MPV.

Abbreviation: MPV, mean platelet volume.
Figure 1 Bar chart of the panic disorder and healthy control groups in terms of MPV.

Table 1 The comparison of the panic disorder and healthy control groups, in terms of sociodemographic characteristics and hemogram results

Discussion

Because the CNS is difficult to access, peripheral platelet models are widely used as indicators of central 5-HT metabolism; moreover, they are known to reflect central serotonergic function.Citation18,Citation21 Platelets are useful models to study intracellular signal transduction eventsCitation22 and have been widely used in psychiatry as a peripheral model of the serotonergic system because they express the 5-HT2A receptors and 5-HT transporters identical to those present in the brain.Citation23

Although three major parameters have been postulated as determinants of platelet volume, including age-dependent processes that can modify platelet size in the circulation, heterogeneity and maturity of the bone marrow megakaryocyte population, and peripheral size-related sequestration of platelets in storage pools,Citation24 there is evidence that MPV is largely determined at or before the time of megakaryocyte fragmentation into platelets.Citation25

There are a few studies that have focused on MPV in psychiatric populations. Ataoğlu and Canan reported that MPV was significantly higher than normal and that escitalopram treatment improved MPV, in patients with major depression.Citation26 However, the mechanism of this increased platelet activity and increased MPV was not obvious. Hausberg et al reported increased sympathetic activity in patients with depression,Citation27 and another study has shown that increased sympathetic activity can also cause higher MPV values.Citation28 Thus, increased sympathetic activity might cause elevated MPV values,Citation29 and this might be the reason for the increased MPV in patients with depression. Similarly Lande et alCitation30 showed that MPV was significantly increased during adrenaline infusion, reflecting either swelling or shape change of platelets due to the activation of platelets or release of larger, activated platelets from the spleen. Researchers suggested that the sympathoadrenal activation may stimulate platelets via 2-adrenoreceptor activationCitation31 and that platelet activation, in turn, causes shape change and thereby increases MPV.Citation32

In our research we found significantly lower MPV values in the PD group than in the healthy population. How does increased sympathoadrenal activation lead to decreased MPV?

In platelets from patients affected by anxiety disorders, modifications in 5-HT transporter levels and activity, as well as abnormalities in 5-HT1A receptor functioning, have been described.Citation33,Citation34 Results of a study by Martini et al suggest that in platelets of PD patients, 5-HT was unable to induce significant phosphorylation of ERK 1 and 2, although their expression levels were not significantly different from healthy volunteers.Citation35 Their results suggested that although no significant alterations of 5-HT1A or 5-HT2A receptor levels have been evidenced in PD, a significant increase in the basal phosphorylation state of these receptor subtypes occurred, likely suggesting specific alterations of the 5-HT receptor functional state in PD. Disordered 5-HT and decreased platelet activity may share a common pathophysiology in some mental disorders. Giret et alCitation36 found decreased platelet 5-HT uptake and decreased platelet monoamine oxidase (MAO) activity in patients with major depression. In another study, patients receiving lithium therapy had increased platelet activity – lithium increases platelet 5-HT type 2 receptor sensitivity, helping to restore the abnormal 5-HT transport rate in patients with mood disorders.Citation37 We can speculate that the abnormal 5-HT metabolism in platelets reflect the abnormal function of platelets, which leads to decreased MPV, a marker and determinant of platelet function.

Despite the findings, some limitations should be noted for the present study. Firstly, the study sample was relatively small, making it difficult to draw definite conclusions. Although all analyses were done in a prespecified protocol, the sample size was not determined before the study start. We obtained sample size from previous studies with similar hypotheses. Secondly, we could not measure inflammatory markers, including the levels of IL-3, thyroid peroxidase (TPO), and in particular, IL-6, which are positively associated with MPV. In addition, this study did not examine either the levels of platelet reactivity or specific receptor pathways of platelet activation. But to the best of our knowledge, this is the first study investigating the MPV in PD.

Conclusion

Although 5-HT as a therapeutic target is widely recognized in the context of the CNS, it is also well established in amplifying platelet activation. MPV may give an indication of platelet activity. The findings of the present study suggest that MPV is decreased in the PD patients. Determining platelet function, which is universally available with routine automated hemograms, may serve as a “window to the brain”.

Disclosure

The authors report no conflicts of interest in this work.

References

  • VanhouttePMPlatelet-derived serotonin, the endothelium, and cardiovascular diseaseJ Cardiovasc Pharmacol199117Suppl 5S6S121717775
  • MarkovitzJHMatthewsKAPlatelets and coronary heart disease: potential psychophysiologic mechanismsPsychosom Med19915366436681758949
  • MercadoCPKilicFMolecular mechanisms of SERT in platelets: regulation of plasma serotonin levelsMol Interv201010423124120729489
  • BakishDCavazzoniPChudzikJRavindranAHrdinaPDEffects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorderBiol Psychiatry19974121841909018388
  • AroraRCMeltzerHYIncreased serotonin2 (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patientsLife Sci198944117257342927243
  • RaoMLHawellekBPapassotiropoulosADeisterAFrahnertCUpregulation of the platelet Serotonin2A receptor and low blood serotonin in suicidal psychiatric patientsNeuropsychobiology199838284899732208
  • EspositoMRubertoMPascottoACarotenutoMNutraceutical preparations in childhood migraine prophylaxis: effects on headache outcomes including disability and behaviourNeurol Sci20123361365136822437495
  • PanconesiASerotonin and migraine: a reconsideration of the central theoryJ Headache Pain20089526727618668197
  • LiuHLiuMWangYAssociation of 5-HTT gene polymorphisms with migraine: a systematic review and meta-analysisJ Neurol Sci20113051–2576621450309
  • BorgdorffPTangelderGJMigraine: possible role of shear-induced platelet aggregation with serotonin releaseHeadache20125281298131822568554
  • SarchielliPAlbertiACoppolaFPlatelet-activating factor (PAF) in internal jugular venous blood of migraine without aura patients assessed during migraine attacksCephalalgia200424862363015265050
  • CarotenutoMEspositoMNutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type INeurol Sci201334111905190923532548
  • ScharingerCRablUKasessCHPlatelet serotonin transporter function predicts default-mode network activityPLoS One201493e9254324667541
  • EllisPMSalmondCIs platelet imipramine binding reduced in depression? A meta-analysisBiol Psychiatry19943652922997993955
  • HamiltonSPLinkage and association studies of anxiety disordersDepress Anxiety2009261197698319842169
  • MaronEShlikJSerotonin function in panic disorder: important, but why?Neuropsychopharmacology200631111116132063
  • KaracetinGBayogluBCengizMSerotonin-2A receptor and catechol-O-methyltransferase polymorphisms in panic disorderProg Neuropsychopharmacol Biol Psychiatry201236151022036916
  • CamachoADimsdaleJEPlatelets and psychiatry: lessons learned from old and new studiesPsychosom Med200062332633610845346
  • ParkYSchoeneNHarrisWMean platelet volume as an indicator of platelet activation: methodological issuesPlatelets2002135–630130612189016
  • FirstMBSpitzerRLGibbonMWilliamsJBWStructured Clinical Interview for DSM-IV Axis I Disorders, Clinical Version (SCID-CV)Washington, DCAmerican Psychiatric Press, Inc1996
  • LeschKPBengelDHeilsAAssociation of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory regionScience19962745292152715318929413
  • AharonovitzOGranotYStimulation of mitogen-activated protein kinase and Na+/H+ exchanger in human platelets. Differential effect of phorbol ester and vasopressinJ Biol Chem19962712816494164998663100
  • CookEHFletcherKEWainwrightMMarksNYanSYLeventhalBLPrimary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptorJ Neurochem19946324654698035173
  • JacksonSRCarterJMPlatelet volume: laboratory measurement and clinical applicationBlood Rev1993721041138369659
  • ThompsonCBLoveDGQuinnPGValeriCRPlatelet size does not correlate with platelet ageBlood19836224874946871471
  • AtaogluACananFMean platelet volume in patients with major depression: effect of escitalopram treatmentJ Clin Psychopharmacol200929436837119593177
  • HausbergMHillebrandUKistersKAddressing sympathetic overactivity in major depressive disorderJ Hypertens200725102004200517885539
  • VizioliLMuscariSMuscariAThe relationship of mean platelet volume with the risk and prognosis of cardiovascular diseasesInt J Clin Pract200963101509151519769707
  • DurmazTÖzdemirÖKeleşTBayramNAAkçayMYeterEPlatelets and sympathetic activity in MITurk J Med Sci2009392259265
  • LandeKGjesdalKFønstelienEKjeldsenSEEideIEffects of adrenaline infusion on platelet number, volume and release reactionThromb Haemost19855424504532417349
  • HjemdahlPLarssonPTWallénNHEffects of stress and beta-blockade on platelet functionCirculation1991846 SupplVI44VI611683610
  • ThompsonCBEatonKAPrinciottaSMRushinCAValeriCRSize dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and functionBr J Haematol19825035095197066203
  • MarazzitiDRossiADell’OssoLDecreased platelet 3H-paroxetine binding in untreated panic disorder patientsLife Sci199965252735274110622283
  • LeschKPWolozinBLMurphyDLReidererPPrimary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporterJ Neurochem1993606231923227684072
  • MartiniCTrincavelliMLTuscanoDSerotonin-mediated phosphorylation of extracellular regulated kinases in platelets of patients with panic disorder versus controlsNeurochem Int200444862763915016478
  • GiretMLaunayJMDreuxCZarifianEBenyacoubKLooHModifications of biochemical parameters in blood platelets of schizophrenic and depressive patientsNeuropsychobiology1980652902967413059
  • WoodKSwadeCAbou-SalehMTCoppenAApparent supersensitivity of platelet 5-HT receptors in lithium-treated patientsJ Affect Disord19858169723156913